The family of interferon (IFN) proteins has now more than reached the potential envisioned
by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical …

Infection with the hepatitis C virus (HCV) represents an important health-care problem
worldwide. The prevalence of HCV-related disease is increasing, and no vaccine is yet …

Aliment Pharmacol Ther 2010; 32: 344–355 Summary Background Most studies evaluating
chronic hepatitis C virus (HCV) natural history have taken the development of cirrhosis as an …

Background Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not
have a sustained virologic response to therapy with peginterferon alfa plus ribavirin …

Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …

Background In phase 2 trials, treatment with the combination of the nucleotide polymerase
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained …

Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and
telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained …

Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with
pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety …

Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …

Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …